145 related articles for article (PubMed ID: 38258519)
1. Discovery of novel and potent CDK8 inhibitors for the treatment of acute myeloid leukaemia.
Chen Z; Wang Q; Yan YY; Jin D; Wang Y; Zhang XX; Liu XH
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2305852. PubMed ID: 38258519
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a novel oral type Ⅰ CDK8 inhibitor against acute myeloid leukemia.
Zhang XX; Yan YY; Ma X; Xiao Y; Lei CC; Wang YM; Liu C; Wang Q; Zhang XT; Cheng WD; Liu XH
Eur J Med Chem; 2023 May; 251():115214. PubMed ID: 36889252
[TBL] [Abstract][Full Text] [Related]
3. MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway.
Lee JC; Liu S; Wang Y; Liang Y; Jablons DM
Oncotarget; 2022 Nov; 13():1217-1236. PubMed ID: 36342456
[TBL] [Abstract][Full Text] [Related]
4. Discovery of the Novel 1
Zhang XX; Xiao Y; Yan YY; Wang YM; Jiang H; Wu L; Shi JB; Liu XH
J Med Chem; 2022 Sep; 65(18):12095-12123. PubMed ID: 36068975
[TBL] [Abstract][Full Text] [Related]
5. Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
Yu M; Teo T; Yang Y; Li M; Long Y; Philip S; Noll B; Heinemann GK; Diab S; Eldi P; Mekonnen L; Anshabo AT; Rahaman MH; Milne R; Hayball JD; Wang S
Eur J Med Chem; 2021 Mar; 214():113248. PubMed ID: 33571827
[TBL] [Abstract][Full Text] [Related]
6. Discovery of N-(2-chloro-5-(3-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide (FD274) as a highly potent PI3K/mTOR dual inhibitor for the treatment of acute myeloid leukemia.
Yang C; Chen Y; Wu T; Gao Y; Liu X; Yang Y; Ling Y; Jia Y; Deng M; Wang J; Zhou Y
Eur J Med Chem; 2023 Oct; 258():115543. PubMed ID: 37329712
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a Potent and Selective FLT3 Inhibitor (
Wang J; Pan X; Song Y; Liu J; Ma F; Wang P; Liu Y; Zhao L; Kang D; Hu L
J Med Chem; 2021 Apr; 64(8):4870-4890. PubMed ID: 33797247
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of indolin-2-one derivatives as novel cyclin-dependent protein kinase 8 (CDK8) inhibitors.
Hsu JY; Hsu KC; Sun C; Chou CH; Lin TE; Sung TY; Tseng HJ; Yen SC; Yang CR; Huang WJ
Biomed Pharmacother; 2023 Mar; 159():114258. PubMed ID: 36708700
[TBL] [Abstract][Full Text] [Related]
9. Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.
Jagtap AD; Chang PT; Liu JR; Wang HC; Kondekar NB; Shen LJ; Tseng HW; Chen GS; Chern JW
Eur J Med Chem; 2014 Oct; 85():268-88. PubMed ID: 25089810
[TBL] [Abstract][Full Text] [Related]
10. Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance.
Hofmann MH; Mani R; Engelhardt H; Impagnatiello MA; Carotta S; Kerenyi M; Lorenzo-Herrero S; Böttcher J; Scharn D; Arnhof H; Zoephel A; Schnitzer R; Gerstberger T; Sanderson MP; Rajgolikar G; Goswami S; Vasu S; Ettmayer P; Gonzalez S; Pearson M; McConnell DB; Kraut N; Muthusamy N; Moll J
Mol Cancer Ther; 2020 Apr; 19(4):1018-1030. PubMed ID: 32024684
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel N-(5-(tert-butyl)isoxazol-3-yl)-N'-phenylurea analogs as potent FLT3 inhibitors and evaluation of their activity against acute myeloid leukemia in vitro and in vivo.
Xu Y; Wang NY; Song XJ; Lei Q; Ye TH; You XY; Zuo WQ; Xia Y; Zhang LD; Yu LT
Bioorg Med Chem; 2015 Aug; 23(15):4333-4343. PubMed ID: 26142317
[TBL] [Abstract][Full Text] [Related]
12. Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.
Li X; Wang A; Yu K; Qi Z; Chen C; Wang W; Hu C; Wu H; Wu J; Zhao Z; Liu J; Zou F; Wang L; Wang B; Wang W; Zhang S; Liu J; Liu Q
J Med Chem; 2015 Dec; 58(24):9625-38. PubMed ID: 26630553
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation.
Yu M; Long Y; Yang Y; Li M; Teo T; Noll B; Philip S; Wang S
Eur J Med Chem; 2021 Jun; 218():113391. PubMed ID: 33823391
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia.
Wang Y; Zhi Y; Jin Q; Lu S; Lin G; Yuan H; Yang T; Wang Z; Yao C; Ling J; Guo H; Li T; Jin J; Li B; Zhang L; Chen Y; Lu T
J Med Chem; 2018 Feb; 61(4):1499-1518. PubMed ID: 29357250
[TBL] [Abstract][Full Text] [Related]
15. Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.
Abdelaziz AM; Diab S; Islam S; Basnet SKC; Noll B; Li P; Mekonnen LB; Lu J; Albrecht H; Milne RW; Gerber C; Yu M; Wang S
Med Chem; 2019; 15(6):602-623. PubMed ID: 30569866
[TBL] [Abstract][Full Text] [Related]
16. Design and Synthesis of 4-(Heterocyclic Substituted Amino)-1
Zhi Y; Wang Z; Yao C; Li B; Heng H; Cai J; Xiang L; Wang Y; Lu T; Lu S
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31731727
[TBL] [Abstract][Full Text] [Related]
17. The discovery of a novel pyrrolo[2,3-b]pyridine as a selective CDK8 inhibitor offers a new approach against psoriasis.
Yan YY; Wang YM; Shen JH; Jian YJ; Lei CC; Wang Q; Liu C; Zhang XX; Liu XH
Biomed Pharmacother; 2024 Jun; 175():116705. PubMed ID: 38713949
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations.
Long Y; Yu M; Ochnik AM; Karanjia JD; Basnet SK; Kebede AA; Kou L; Wang S
Eur J Med Chem; 2021 Mar; 213():113215. PubMed ID: 33516985
[TBL] [Abstract][Full Text] [Related]
19. Discovery and Anti-Inflammatory Activity Evaluation of a Novel CDK8 Inhibitor through Upregulation of IL-10 for the Treatment of Inflammatory Bowel Disease
Yan Y; Xing C; Xiao Y; Shen X; Zhang Z; He C; Shi JB; Liu M; Liu X
J Med Chem; 2022 May; 65(10):7334-7362. PubMed ID: 35536548
[TBL] [Abstract][Full Text] [Related]
20. Discovery of orally active indirubin-3'-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia.
Jeong P; Moon Y; Lee JH; Lee SD; Park J; Lee J; Kim J; Lee HJ; Kim NY; Choi J; Heo JD; Shin JE; Park HW; Kim YG; Han SY; Kim YC
Eur J Med Chem; 2020 Jun; 195():112205. PubMed ID: 32272419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
